Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients

Assaid, Najlaa; Arich, Soukaina; Charoute, Hicham; Akarid, Khadija; Sadat, Mohamed Anouar; Maaroufi, Abderrahmane; Ezzikouri, Sayeh; Sarih, M’hammed

doi:10.4269/ajtmh.22-0448

Cited by 13 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we did not confirm an association between gender type and the prevalence of antibodies, which is also consistent with the results of the study by Assaid et al (7).…”

Section: Discussionsupporting

confidence: 90%

“…The study by Assaid et al monitored by ELISA (enzyme-linked immunosorbent assay) the appearance of IgG and IgM antibodies at 3 months after the onset of COVID-19. In their study (7), they showed that IgG antibodies appeared between 2 weeks and one month after the onset of infection, persisted for 3 months in 79% of the probands studied, and then gradually decreased in levels. In contrast, 19% of probands had declining IgM antibodies after the first month of symptom onset.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Prevalence of COVID-19 antibodies in employees of St. Jacob Hospital in Bardejov

Konečná,

Maxinová,

Mihalcová

et al. 2023

Cent Eur J Public Health

View full text Add to dashboard Cite

Objective: The COVID-19 disease caused by the SARS-CoV-2 virus belongs to the group of highly infectious diseases with increased mortality and morbidity in the population. Finding the presence of antibodies plays an important role while finding the number of individuals who overcame the disease or were vaccinated.Methods: A total of 250 employees of St. Jacob Hospital with Polyclinic, Bardejov, participated in our study, the blood samples were drawn from the index finger and processed with the help of the rapid Ag test for the detection of antibodies and venous blood using the ELISA method. The health workers (doctors, nurses, medical laboratory technicians, laboratory diagnosticians) tested during September and October 2022 participated in our study.Results: Our experimental study shows the presence of IgG antibodies in 215 (86%) of employees, who get them from overcoming the COVID-19 disease or getting vaccinated. In 17 (6.8%) of employees were detected IgG and IgM antibodies. The biggest number of IgG antibodies was found in 36 (78%) employees of the Surgical Department, 28 (84%) employees of Rehabilitation Department and 25 (89%) employees of the Internal Department, when compared with the Department of Laboratory Medicine 9 (30%) employees and Radiology Department 4 (44%) employees.Conclusion: Multiple prevalence of COVID-19 disease were found in employees of the internal, surgical and rehabilitation departments in whom we detected a higher presence of IgG antibodies. In department of laboratory medicine workers were proven lower levels of IgG antibodies, mainly for the limited contact with the positive covid patients and working with only their biological material, compared to the first-line employees exposed to direct contact with the patients.

show abstract

“…In our study, we did not confirm an association between gender type and the prevalence of antibodies, which is also consistent with the results of the study by Assaid et al (7).…”

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 95%

Prevalence of COVID-19 antibodies in employees of St. Jacob Hospital in Bardejov

Konečná,

Maxinová,

Mihalcová

et al. 2023

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…In general, IgA and IgM antibodies are generated earlier than IgG isotypes, with earlier detection of IgA than IgM and remarkable persistence of IgG over time [ 39 – 41 ]. We previously described the kinetics of anti-N IgM and anti-S IgG antibody responses up to 3 months after natural infection using a commercial Euroimmun ELISA [ 42 ]. In this study, we used several serological assays to measure IgA and IgM antibodies levels against the nucleocapsid protein (NCP) at 1 month after symptom onset, and monitored IgG against the RBD in the S1 subunit and anti-N IgG up to 1 year after infection.…”

Section: Discussionmentioning

confidence: 99%

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Coronavirus 2019 (COVID-19) is a global health threat. The kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be assessed, as the long-term duration of these immunoglobulins remains largely controversial. The aim of this study was to assess the longitudinal dynamics of anti-SARS-CoV-2 antibodies against the nucleocapsid (N) protein and the receptor-binding domain (RBD) of the spike protein up to one year in a cohort of 190 COVID-19 patients. Between March and September 2021, we enrolled patients from two regional hospitals in Casablanca, Morocco. Blood samples were collected and analyzed for antibody levels. We used the commercial Euroimmun ELISA for the determination of anti-N IgM, the Abbott Architect™ SARS-CoV-2 IgG test for the detection of anti-RBD IgG, and an in-house kit for the assay of anti-N IgG and anti-N IgA. IgM and IgA antibodies were assessed 2–5, 9–12, 17–20 and 32–37 days after symptom onset. IgG antibodies were also assessed 60, 90, 120 and 360 days after symptom onset. One-third of patients developed IgM (32%), while two-thirds developed IgA (61%). One month of symptom onset, most patients developed IgG, with 97% and 93% positivity for anti-RBD IgG and anti-N IgG, respectively. The anti-RBD IgG positivity rate remained high up to one year of follow-up. However, the anti-N IgG positivity rate decreased over time, with only 41% of patients testing positive after one year’s follow-up. IgG levels were significantly higher in older people (over 50 years) than in other study participants. We also found that patients who had received two doses of ChAdOx1 nCoV-19 vaccine prior to infection had a lower IgM response than unvaccinated patients. This difference was statistically significant two weeks after the onset of symptoms. We present the first study in Africa to measure the kinetics of antibody response (IgA, IgM and IgG) to SARS-CoV-2 over one year. Most participants remained seropositive for anti-RBD IgG after one year but showed a significant decline in antibody titers.

show abstract

“…Seropositivity to anti-SARS-CoV-2 antibodies was used as a biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were used as a marker of recent or current infection (usually from days 5-7 after symptoms appear, but sometimes later and decrease at days 15-22), and IgG class immunoglobulins were used as a biomarker of older infection (detectable from day 11 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29, 30]. Serological tests were performed by qualitative ELISA for IgM and quantitative ELISA for IgG following the instructions for the WANTAI SARS-CoV-2 IgM ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China; Ref.…”

Section: Methodsmentioning

confidence: 99%

“…Seropositivity to anti-SARS-CoV-2 antibodies was used as a biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were used as a marker of recent or current infection (usually from days 5-7 after symptoms appear, but sometimes later and decrease at days [15][16][17][18][19][20][21][22], and IgG class immunoglobulins were used as a biomarker of older infection (detectable from day 11 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29,30]. recommended by the WHO for seroepidemiological studies, which detects total antibodies (including IgM and IgG) binding the SARS-CoV-2 spike protein receptor binding domain (S1/RBD) [31].…”

Section: Blood Collection and Sars-cov-2 Antibodies Detectionmentioning

confidence: 99%

Serological Survey in a university community after the fourth wave of COVID-19 in Senegal

Thiam,

Diouara,

Ndiaye

et al. 2024

Preprint

View full text Add to dashboard Cite

Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure among students and staff of Polytechnic High School (PHS). Random cluster sampling was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated. Moreover, the associations between seropositivity and different factors (age, gender, preventive, etc.) were determined using logistic regression. A total of 637 participants were recruited, including 563 students, followed by 52 TAS officers, and 22 professors. The median age among was 21 years [18 - 63]. 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM seroprevalence were 92% and 6.91% respectively. We found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence in (18-25) age group compared to (55-65) years. Low compliance with preventive measures was found with a significant IgM seroprevalence depending on non-respect of social distancing (p = 0.008). IgM seropositivity was associated with Body Mass Indice (BMI) categorized (O.R. 0.238, p = 0.043), ethnic group (O.R. 0.723, p = 0.046) and marital status (O.R. 2.399, p = 0.021). Moreover, IgG seropositivity was associated with vaccination status (O.R. 4.741, p < 0.001). Our study revealed that the majority of students and staff have already been exposed to SARS-CoV-2, which confirms the circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the importance of seroepidemiological surveys to estimate the real impact of the COVID-19 pandemic in a community and to monitor disparities in antibody response in the population.

show abstract

Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients

Cited by 13 publications

References 54 publications

Prevalence of COVID-19 antibodies in employees of St. Jacob Hospital in Bardejov

Prevalence of COVID-19 antibodies in employees of St. Jacob Hospital in Bardejov

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

Serological Survey in a university community after the fourth wave of COVID-19 in Senegal

Contact Info

Product

Resources

About